Silexion Therapeutics (SLXN) AI Stock Analysis

• Market Cap: $7.04M
• Dividend Yield: N/A
• Average Volume (3M): 623.93K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.09
• Revenue Growth: N/A
• EPS Growth: -73095.97%
• Country: US
• Employees: 11
• Sector: Financial
• Sector Strength: 80
• Industry: Biotechnology
• EPS (TTM): -19.98
• Shares Outstanding: 8,692,392
• 10 Day Avg. Volume: 91,539
• 30 Day Avg. Volume: 623,933
• PEG Ratio: 0.00
• Price to Book (P/B): -13.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -42.39
• Enterprise Value/Market Cap: 19.18
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -2.67
• 1Y Price Target: $5.00
• Price Target Upside: 449.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 34 Underperform
• Price Target: ―

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

Positive Factors

Development progress

Silexion plans to submit a Clinical Trials Application (CTA) in the EU and initiate Phase 2/3 study, indicating progress in the drug's development.

Market opportunity

The global treatment market for cancers with KRAS mutations is estimated at over $30 billion annually, highlighting a significant commercial opportunity.

Pre-clinical data

Silexion announced positive pre-clinical data finding SIL-204 demonstrated anti-tumor activity in additional cancers including colorectal and lung cancers harboring KRAS mutations.

Negative Factors

Price target adjustment

The 12-month price target has been lowered to $5.00, from $9.00 due to the additional dilution from the recent capital raise and warrant exercises.

Sales risk

A 30% sales risk-adjustment is applied to SIL-204 based on stage of development, PDUFA risks, and commercial risks.

Silexion Therapeutics Business Overview & Revenue Model

Company Description

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

How the Company Makes Money

Silexion Therapeutics generates revenue primarily through the sale of its proprietary pharmaceutical products, which are developed in-house and marketed globally. The company also engages in licensing agreements with other pharmaceutical firms, allowing them to commercialize Silexion's patented technologies in exchange for royalties and milestone payments. Additionally, strategic partnerships with research institutions and healthcare providers contribute to its earnings by facilitating collaborative development projects and expanding its market reach.

Silexion Therapeutics Financial Statement Overview

Summary

Silexion Therapeutics faces significant financial challenges, including zero revenue and negative equity, posing major risks. While there is an improvement in net income and operating cash flow, the lack of revenue generation and high leverage create concerns for future sustainability.

Income Statement

Silexion Therapeutics has consistently reported zero revenue over the past three years, which is concerning for a company in the biotechnology industry. The net income improved significantly in 2024, turning positive after previous losses, indicating potential improvements in cost management or business operations. However, the lack of revenue generation remains a critical issue.

Balance Sheet

The balance sheet shows significant challenges, with stockholders' equity being negative in recent years and total liabilities exceeding total assets. The company's debt-to-equity ratio cannot be calculated due to negative equity, and this financial structure indicates high leverage and potential solvency risks. The absence of cash and cash equivalents in 2024 further adds to liquidity concerns.

Cash Flow

The cash flow position has seen some improvement, with operating cash flow increasing significantly towards a less negative figure in 2024. However, free cash flow remains negative, indicating ongoing challenges in generating cash from operations even though there is a positive shift in financing cash flow. The negative free cash flow to net income ratio suggests that the company is not yet in a stable cash generation position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
EBITDA	-17.06M	-16.43M	-4.64M	-3.80M
Net Income	-16.81M	16.51M	-4.94M	-3.21M
Balance Sheet
Total Assets	8.31M	2.86M	5.26M	9.33M
Cash, Cash Equivalents and Short-Term Investments	6.15M	1.22M	4.59M	8.26M
Total Debt	489.00K	4.49M	171.00K	271.00K
Total Liabilities	5.72M	6.85M	17.31M	16.41M
Stockholders Equity	2.59M	-3.99M	-15.48M	-10.66M
Cash Flow
Free Cash Flow	-9.12M	-8.42M	-4.54M	-3.38M
Operating Cash Flow	-9.10M	-8.40M	-4.53M	-3.33M
Investing Cash Flow	-22.00K	-22.00K	573.00K	-524.00K
Financing Cash Flow	12.54M	5.10M	522.00K	2.75M

Silexion Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.91
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLXN, the sentiment is Neutral. The current price of 0.91 is above the 20-day moving average (MA) of 0.83, below the 50-day MA of 0.91, and below the 200-day MA of 1.85, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 59.37 is Neutral, neither overbought nor oversold. The STOCH value of 68.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SLXN.

Silexion Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	64 Neutral	$6.51B	11.17	7.19%	226.02%	23.75%	4.96%
APLM	42 Neutral	$7.11M	―	-233.67%	―	―	-1786.46%
PTNT	41 Neutral	$6.74M	―		―	-94.07%	52.36%
SNGX	39 Underperform	$3.66M	―	-437.73%	―	―	57.83%
SLXN	34 Underperform	$7.04M	―	-590.37%	―	―	-73095.97%
RNAZ	27 Underperform	$7.71M	―	-342.99%	―	―	99.64%
OCEA		$1.67M	―		―	―	―

Silexion Therapeutics Corporate Events

Silexion Therapeutics Partners with Catalent for SIL204 Development

On April 23, 2025, Silexion Therapeutics announced a strategic collaboration with Catalent to develop advanced siRNA formulations and conduct clinical manufacturing activities for SIL204, their next-generation siRNA candidate. This partnership aims to optimize SIL204’s delivery formulations for targeting KRAS-driven cancers, building on promising preclinical results and supporting Silexion’s strategy to advance SIL204 toward clinical trials, with potential regulatory submissions planned for 2025 and 2026.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics is currently facing significant financial challenges, with zero revenue and negative equity posing major risks. The technical analysis reflects bearish momentum, and the valuation metrics highlight the speculative nature of the stock. However, recent corporate events, particularly the progress in SIL204, provide some optimism. Overall, the stock’s score is low, reflecting the high risks and uncertain future prospects.

To see Spark’s full report on SLXN stock, click here.

Silexion Therapeutics Expands SIL204 Development Plan

On March 28, 2025, Silexion Therapeutics announced an expanded development plan for its siRNA candidate, SIL204, following promising preclinical data. The plan includes a dual-route administration strategy to treat KRAS-driven pancreatic cancer, integrating systemic and intratumoral delivery methods. This approach aims to address the aggressive nature of KRAS-driven cancers, characterized by high mortality and limited treatment options. Building on previous clinical results, Silexion plans further studies and regulatory submissions in 2025 and 2026, potentially advancing SIL204 into the next stage of clinical development.

Silexion Therapeutics Reports Positive Data for SIL204

On March 5, 2025, Silexion Therapeutics announced positive initial data from the systemic administration of SIL204 in orthotopic pancreatic cancer models. The data demonstrated SIL204’s efficacy in reducing both primary tumor growth and metastatic spread, marking a significant advancement in their development program. The findings validate SIL204’s effectiveness in a clinically relevant setting and suggest potential for treating both primary and metastatic pancreatic cancer with a minimally-invasive delivery method. Silexion is exploring an expanded development plan for SIL204 based on these results.